|
Pharma & Healthcare
|
|
|
Expectation
|
Probability
|
Implications
|
Extension of the list of Drugs under DPCO
|
Low
|
Negative for the Pharma companies deriving larger % of sales from the drugs under DPCO
|
Change in transfer pricing policy (API attracts 10% excise duty whereas formulations 4%)
|
Medium
|
Good for the companies having vertical integration (Lupin, Dr Reddy, Sun Pharma, IPCA, Unichem, etc)
|
Infrastructure status to Healthcare
|
Medium
|
Good for Apollo Hospital and Fortis
|
Extension of tax exemption beyond FY11 in EOUs
|
Medium
|
Good for Dishman, Cipla, Divis, IPCA, Unichem, Torrent, etc
|
Exemption of central excise duty on physician samples
|
Low
|
Good for overall Pharma Sector
|
Extension of weighted deduction on R&D on all research related services (currently in-house R&D at 200%)
|
Low
|
Good for overall Pharma Sector
|
Also view other Sectoral Expectations:
|